InspireMD (NSPR) Stock Price, News & Analysis

Company Overview

InspireMD, Inc. is a medical device company focused on developing and commercializing products for the treatment of carotid artery disease and the prevention of stroke. Its technology is designed to support minimally invasive procedures that restore blood flow in narrowed or blocked arteries while helping to reduce the risk of embolic debris reaching the brain.

The company’s principal product is the CGuard carotid embolic prevention system, which combines a self-expanding carotid stent with a proprietary microNet mesh intended to trap plaque and other debris against the arterial wall during and after carotid artery stenting. InspireMD has developed multiple iterations of the platform, including CGuard Prime, and has pursued regulatory approvals and clinical adoption in the United States and international markets.

InspireMD was founded in 2005 and is headquartered in Tel Aviv, Israel. The company serves physicians and healthcare providers through a global commercial and distribution network, with a strategic focus on expanding the use of its carotid stenting technology in the United States and other markets. Marvin Slosman serves as chief executive officer.

Key Stats

• Today's Range: $0.44 to $0.50
• 50-Day Range: $0.44 to $0.92
• 52-Week Range: $0.43 to $2.41
• Volume: 169,503 shs
• Average Volume: 146,789 shs
• Market Capitalization: $20.89 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.50
• Consensus Rating: Buy

InspireMD Stock Analysis - MarketRank™

InspireMD scored higher than 42% of companies evaluated by MarketBeat, and ranked 629th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

InspireMD has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

InspireMD has a consensus price target of $4.50, representing about 901.6% upside from its current price of $0.45.

Amount of Analyst Coverage

InspireMD has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for InspireMD are expected to grow in the coming year, from ($0.79) to ($0.73) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of InspireMD is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of InspireMD is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

InspireMD has a P/B Ratio of 0.25. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for NSPR.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

InspireMD does not currently pay a dividend.

Dividend Growth

InspireMD does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added InspireMD to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, InspireMD insiders have not sold or bought any company stock.

Percentage Held by Insiders

24.98% of the stock of InspireMD is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

44.78% of the stock of InspireMD is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/12/2024
• Today: 10/26/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NYSE:NSPR
• CIK: 1433607
• Web: www.inspiremd.com
• Phone: 9728887766804
• Fax: N/A
• Employees: 127
• Year Founded: N/A

Price Target and Rating

• Average Price Target for InspireMD: $4.50
• High Price Target: $6.00
• Low Price Target: $3.00
• Potential Upside/Downside: +901.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$19.92 million
• Net Margins: -413.96%
• Pretax Margin: -413.00%
• Return on Equity: -69.42%
• Return on Assets: -57.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.39
• Quick Ratio: 6.05

Sales & Book Value

• Annual Sales: $10.84 million
• Price / Sales: 1.93
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.83 per share
• Price / Book: 0.25

Miscellaneous

• Outstanding Shares: 46,489,000
• Free Float: 18,332,000
• Market Cap: $20.89 million
• Optionable: Optionable
• Beta: 0.84